Whether you're focused on TCR discovery, T-cell profiling, cell therapy, antibody discovery, or cell line development, the Beacon is designed to elevate your work to new heights.
Join us at this seminar
After finishing his BSc with honours in immunology at the University of Edinburgh, Darryl completed his PhD in Victor Tybulewicz’s lab at the Francis Crick Institute working on the role of the WNK1 kinase in B cell biology. Over the last three years, Darryl has been working in the in vivo antibody discovery team at GSK. Here, Darryl has been developing their Beacon screening platform to allow for enhanced screening during antibody discovery.
Rennos Fragkoudis completed his PhD on molecular virology at the University of Edinburgh and for more than 15 years he concentrated his research on the pathogenesis of arthropod-borne viruses (arboviruses) in both vertebrate and invertebrate systems working with alpha-, flavi- and bunyaviruses.
In November 2019 he returned to the University of Edinburgh where he is the Head of the Edinburgh Genome Foundry. Together with the Foundry team, Rennos promotes the usage of automation across all disciplines of Life Sciences and actively expands the capabilities of the Foundry.
Dr Kirsty McHugh is a Senior Postdoctoral Scientist in Simon Draper’s Blood-stage malaria research group in Oxford, and a Fellow in Biochemistry at Pembroke College. She completed her DPhil in Clinical Medicine at the Weatherall Institute of Molecular Medicine in the Arthritis group headed by Paul Bowness, before moving to the Botnar Research Centre to continue postdoctoral research into the role of HLA-B27 in arthritis. She joined the Draper group in 2015 to work on developing novel monoclonal antibody therapeutic interventions for hematological disorders before switching her focus to infectious disease. Her research now centers around isolating monoclonal antibodies to better understand vaccine-induced antibody responses. Through a better understanding of the epitope landscape of vaccine antigens she hopes to help guide the design of next-generation malaria vaccines.
Professor Stefan Eichmüller, PhD, is a prominent researcher and the Head of the Research Group GMP & T Cell Therapy at the German Cancer Research Center (DKFZ). He specializes in the development and optimization of T cell therapies for cancer treatment, focusing on Good Manufacturing Practice (GMP) standards. With extensive experience in immunology and cellular therapies, Dr. Eichmüller has contributed significantly to advancing therapeutic strategies in oncology. He is also a Qualified Person, ensuring compliance with regulatory requirements for the production of cell-based therapies. His work is pivotal in bridging the gap between laboratory research and clinical application, aiming to improve patient outcomes in cancer treatment.
What to expect
| 12:15 PM | Registration and Lunch |
| 1:00 PM |
Welcome Maria Walton, Account Executive at Bruker Cellular Analysis |
| 1:10 PM |
Beacon Technology Overview Thomas Adejumo, Market Development Representative at Bruker Cellular Analysis |
| 1:40 PM |
High-throughput Isolation and Characterization of Monoclonal Antibodies to Blood-Stage Malaria Vaccine Candidates Kirsty McHugh, Senior Postdoctoral Scientist, Blood Stage Malaria Group at University of Oxford |
| 2:10 PM |
Enhancing Antibody Discovery Using the Beacon Platform Darryl Hayward, Antibody Discovery B Cell Scientist at GSK |
| 2:40 PM | Coffee Break |
| 3:10 PM |
Of DNA & Robots: The Edinburgh Genome Foundry Rennos Fragkoudis, Facility Manager Edinburgh Genome Foundry at University of Edinburgh |
| 3:40 PM |
Myeloma-specific T Cells Identified in Single Cell Interaction Experiments on the Lightning Platform Stefan Eichmüller, Head of Research Group GMP & T Cell at German Cancer Research Center, DKFZ |
| 4:10 PM | Panel Discussion |